Testing Nemtabrutinib in People with Severe Kidney Disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine (nemtabrutinib) in people with severe kidney disease to see how the body handles it. The study helps doctors decide safe doses for people with kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe kidney disease (severe renal impairment).
- Your kidney function has been stable, as shown by recent medical tests.
- You do not have other major illnesses besides kidney disease that could confuse the results or add risk.
- Your body mass index (BMI) is between 18 and 40.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, KR23343, in healthy adults to see how the body handles it at different doses. It helps find the right dose and check for any early side effects.
This study tests how the body processes the experimental medicine PF-07328948 in people with different levels of kidney function. It may help find the right dose for people with kidney disease.
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
Hear when a new Severe Renal Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.